DRUG PRIOR AUTHORIZATION COMMITTEE MEETING

**March 17, 2016**

La Charette/Nightingale Rooms, 1101 Riverside Drive, Jefferson City, MO

|  |  |
| --- | --- |
| **Committee Members Present**Conrad Balcer, D.OPatrick Bryant, Pharm D Jennifer Kemp-Cornelius, Pharm DGene Forrester, R. Pharm DMorgan Sperry, Pharm D- \* Non-voting member this mtg.Laine Young-Walker, M.D. | MO HealthNet Staff Present:Stephen Calloway, R.Ph, Director of PharmacyMark Roaseau, R.Ph, Clinical PharmacistJenna McTeer, RN, Clinical ManagementAngela Wilson, Manager, Band IMegan Goldthrite, Administrative AssistantAndrew Haslag, Fiscal ManagerElizabeth Short, Medicaid SpecialistLisa E. Smith, Medicaid SpecialistChristine Thompson, Fiscal Unit ManagerDr. Timothy Kling, MD, Assistant Medical Director |

**Contractors in Attendance:**

Kathleen Wilbers, Pharm D, Xerox

Joshua Moore, Pharm D, Xerox

Luke Boehmer, Pharm D, Xerox

Rick Pope, Pharm D, Magellan

|  |
| --- |
| Others Attending: |
| Todd Herman, MerckTony Jelinek, Rickett BenckiserJennifer Wilbanks, Otsuka Barry Watkins, RelypsaSteven Woods, RelypsaMichael Lafond, AbbvieAmy Christensen, NovartisBrent Fushimi, ArberCamille Kerr, AmgenTim Ludlan, Allergen | Ashley Polce, AbbvieMike Donze, BIJason Klump, BILisa Tootle, BMSMelissa Laurie, BMSPhil King, PfizerKen Lundwig, The Medicine CompanyMichele Puyear, GileadBrian Strickland, GileadBerend koops, Merck | Stephanie Keithly, Novo NordiskJim Baumann, PfizerDel Deem, Astra Zeneca |

.

|  |  |
| --- | --- |
| **Welcome, Introductions and Opening Remarks** | Conrad Balcer, D.O., Acting Committee Chairman, called the meeting to order. Stephen Calloway introduced himself and started the introductions and opening remarks.  |
| **Minutes Approval**  | Minutes of the December 15, 2015 Drug PA meeting were reviewed and approved. Conrad Balcer, D.O. motioned and Pat Bryant seconded the motion. (See Roll Call Vote) |
| **Pharmacy Program/Budget Update** | Stephen Calloway presented a brief slideshow. The presentation contained graphs representing demographic information about MHD participants, drug expenditures by participant groups, drug class, and program. Information was also provided on selected drug expenditures and initiatives MHD is tracking.  |
| **DUR Report** | Stephen Calloway stated all PDL Renewals from the December 2015 Drug PA Meeting were ratified at the January 2016 DUR Board Meeting. |
| **Old Business** |
| **Implementation Schedule**  | An updated copy of the Proposed Implementation Schedule for Edits, including PDL classes was included in the Members’ meeting packet and provided as a handout to all attending. The schedule included the therapeutic classes will be implemented July 2016. PDL decisions from December/January will be implemented April 2016. Schedules may be found on the MHD web page at <http://dss.missouri.gov/mhd/cs/pharmacy/impsched.pdf>  |
| **New Business** |
| **New Drug Review** | Stephen Calloway reviewed the new drug products that were identified for the quarter October, November, December 2015 and the recommended status within the clinical program.**• Discussion –** A listing of products recommended for open access, clinical edit, preferred drug list (PDL) product, or continued prior authorization was provided in the Members’ meeting packet for discussion and action. This listing was also provided as a handout to all attending. **• Decision –** Members voted to accept the new drug recommendations as presented. (See Roll Call Vote) |
| **Clinical Edits** |
| **Orkambi** | **• Discussion –** Mr. Calloway stated there were changes for this class.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Transmucosal Immediate – Orkambi Release Fentanyl (TIRF)** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.**• Public Hearing –** No Comments Entered. |
| **Short – Acting Narcotics** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.**• Public Hearing –** No Comments Entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Prefereed Drug List (PDL)** |  |
|  **Benzoyl Peroxide Clindamycin** | **• Discussion – –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
|  **Beta Adrenergic LA** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.**• Public Hearing –** No Comments Entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
|  **Beta Adrenergic Nebulized** | **• Discussion – –** Mr. Calloway stated no changes as recommended for this class. **• Public Hearing –** No comments entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
|  **Beta Adrenergic SA** | **• Discussion – –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.**• Public Hearing –** No comments entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
|  **COPD Anticholinergics** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.**• Public Hearing –** No comments entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
|  **Cough and Cold Agents** | **• Discussion –** Mr. Calloway stated no changes as recommended for this class.**• Public Hearing –** No comments entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
|  **Herpes Antivirals** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.**• Public Hearing –** No comments entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
|  **Inhaled Antibiotics** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.**• Public Hearing –** No comments entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Inhaled Corticosteroids** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Intranasal Antihistamines** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.**• Public Hearing –** No comments entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Leukotriene Modifiers** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Low Sedating Antihistamines** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Low Sedating Antihistamine/Decongestant Combinations** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Nasal Steroids** |  **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Onychomycosis Antifungals** |  **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Ophthalmic Antihistamines** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. **• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Ophthalmic Mast Cell Stabilizers** | **• Discussion –** Mr. Calloway stated there are no changes recommended for this class.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Ophthalmic NSAIDS** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Ophthalmic Prostaglandin Agonists** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Otic Fluoroquinolones** | **• Discussion –** Mr. Calloway stated there are no changes recommended for this class.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Pancreatic Enzymes** | **• Discussion –** Mr. Calloway stated there are no changes recommended for this class.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Self-Injectable Epinephrine Agents** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Topical Agents for Psoriasis** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Topical Androgenic Agents** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Topical Antifungals** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Topical Antiparasitics** | **• Discussion –** Mr. Calloway stated there are no changes recommended for this class.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Topical Antivirals** | **• Discussion –** Mr. Calloway stated there are no changes recommended for this class.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Topical Immunomodulators (Atopic Dermatitis)** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Topical Retinoids** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Topical Steroids** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Ulcerative Colitis Agents - Oral** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Ulcerative Colitis Agents - Rectal** | **• Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.**• Public Hearing –** No comments were entered.**• Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote) |
| **Preferred Drug List Announcement** | A handout of therapeutic categories to be reviewed for inclusion on the Preferred Drug List for the next phase and meeting was included in the meeting packet. This handout was also provided to all attendees and will be posted to the Division's web page: <http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf> |
| **Xerox Update** | Luke Boehmer, PharmD reviewed clinical edits, utilization data and trends for DMARDS. Also, spoke about the different reasons for denials. Then he spoke about the Opiate Dependence Agents. |
| **Program Utilization:****Top 25 Drugs Summary** | Dr. Boehmer reviewed the Top 25 Drugs Summary Reports for the 3rd and 4th quarter of 2015. Two versions were presented: one report ranked drug spend by dollars and the other by utilization/claims. |
| **Call Center Statistics**  | A handout detailing pharmacy help desk call center activity was provided for all attending. Cyber Access Active User Counts and Logging Information reports detailing activity were shared. Dr. Boehmer reviewed how many sites/physical locations are trained and have access to CyberAccess. Reports also detailed the number and type of prescribers and active users on CyberAccess |
| **Adjourn** | The meeting was adjourned. The next meeting of the Drug Prior Authorization Committee is scheduled for Thursday, June 15, 2016.Attendees were advised to check the [calendar of events](http://www.dss.mo.gov/mhd/global/pages/calendar.htm) on the MHD website for meeting location changes over the next few months. (See attached roll call) |

 **Roll Call Votes – March 17, 2016**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Member | Minutes | New Drugs Review | Benzoyl Peroxide/ClindamycinTopical Agents | Beta - Adrenergic Agents: Long Acting | Beta - Adrenergic Agents: Nebulized | Beta - Adrenergic Agents: Short Acting | COPD Anticholinergics |
| Conrad Balcer, D.O. | YM | Y | Y | Y | Y | Y | Y |
| Pat Bryant, Pharm D | YS | YM | YM | YS | YS | YM | YS |
| Gene Forrester, R. Pharm D | Y | Y | Y | Y | Y | Y | YM |
| Laine Young-Walker, M.D. | Y | Y | Y | Y | Y | YS | Y |
| Morgan Sperry, Pharm D |  |  |  |  |  |  |  |
| Jennifer Kemp-Cornelius, Pharm D | Y | YS | YS | YM | YM | Y | Y |

**Roll Call Votes – March 17, 2016**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Member | Cough & Cold Agents |  Herpes (Oral) Antivirals |  Inhaled Antibiotics | Inhaled Corticosteroid | Intranasal Antihistamines | Leukotriene Modifiers |
| Conrad Balcer, D.O. | Y | Y | Y | Y | Y | Y |
| Pat Bryant, Pharm D | YM | YM | YM | Y | YS | Y |
| Gene Forrester, R. Pharm D | Y | Y | Y | Y | Y | YS |
| Laine Young-Walker, M.D. | YS | YS | YS | YM | YM | Y |
| Morgan Sperry, Pharm D |  |  |  |  |  |  |
| Jennifer Kemp-Cornelius, Pharm D | Y | Y | Y | YS | Y | YM |

**Roll Call Votes – March 17, 2016**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Member | Low Sedating Antihistamines | Low Sedating Antihistamines/Decongestant Combinations | Ophthalmic Antihistamines | Ophthalmic Mast Cell Stabilizers | Ophthalmic NSAIDS | Ophthalmic Prostaglandin Agonists | Ophthalmic Quinolones |
| Conrad Balcer, D.O. | Y | Y | Y | Y | Y | Y | Y |
| Pat Bryant, Pharm D | YS | Y | YS | YM | Y | Y | YM |
| Gene Forrester, R Pharm D | Y | Y | Y | YS | Y | YS | YS |
| Laine Young-Walker, M.D. | YM | YM | YM | Y | YM | Y | Y |
| Morgan Sperry, Pharm D |  |  |  |  |  |  |  |
| Jennifer Kemp-Cornelius, Pharm D | Y | YS | Y | Y | YS | YM | Y |

**Roll Call Votes – March 17, 2016**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Member | Onychomycosis Antifungals | Nasal Steroids | Otic Quinolones | Pancreatic Enzymes | Self - Injectible Equipment Agents | Topical Agents for Psoriasis |
| Conrad Balcer, D.O. | Y | Y | Y | Y | Y | Y |
| Pat Bryant, Pharm D | YS | Y | YS | YM | Y | YM |
| Gene Forrester, R. Pharm D | Y | Y | Y | YS | Y | YS |
| Laine Young-Walker, M.D. | YM | YM | YM | Y | YM | Y |
| Morgan Sperry, Pharm D |  |  |  |  |  |  |
| Jennifer Kemp-Cornelius, Pharm D | Y | YS | Y | Y | YS | Y |

**Roll Call Votes – March 17, 2016**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Member | Topical Androgenic Agents | Topical Antifungals |  Topical Antiparasitics |  Topical Antivirals |  Topical Immunomodulators (Atopic Dermatitis) | Topical Steroids |
| Conrad Balcer, D.O. | Y | Y | Y | Y | Y | Y |
| Pat Bryant, Pharm D | Y | Y | Y | YS | YM | YS |
| Gene Forrester, R. Pharm D | YS | Y | YS | YM | Y | Y |
| Laine Young-Walker, M.D. | Y | YM | YM | Y | Y | YM |
| Morgan Sperry, Pharm D |  |  |  |  |  |  |
| Jennifer Kemp-Cornelius, Pharm D | YM | YS | Y | Y | YS | Y |

**Roll Call Votes – March 17, 2016**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Member | Ulcerative Colitis Agents - Oral | Ulcerative Colitis Agents - Rectal | Topical Retinoids |  Motion To Close |   |   |   |
| Conrad Balcer, D.O. | Y | Y | Y | Y  |  |   |   |
| Pat Bryant, Pharm D | YM | YM | YS | YS  |   |   |   |
| Gene Forrester, R. Pharm D | YS | Y | Y | Y  |   |   |   |
| Laine Young-Walker, M.D. | Y | YS | Y | Y  |   |   |   |
| Morgan Sperry, Pharm D |  |  |  |  |  |  |  |
| Jennifer Kemp-Cornelius, Pharm D | Y | Y | YM |  YM |   |   |   |